![FDA-sign](https://pharmaphorum.com/wp-content/uploads/2016/05/FDA-sign.jpg)
FDA knocks back MEI's plans for drug in troubled PI3K class
MEI Pharma and partner Kyowa Kirin have had to abandon plans to file for approval of their PI3K inhibitor zandelisib in B cell lymphoma, after being "discouraged" by the FDA from making the